Access for:
The report shows potential savings that may be achieved by prescribing generically. The specialist drugs report is produced at national, ICB, commissioner / provider and practices.
They include the potential generic savings report which is produced at national, ICB, commissioner / provider, practice level and practices within a commissioner / provider.
This is a list of drugs, identified by advisers, to help with the monitoring of drugs there are concerns about in relation to appropriate prescribing in primary care. Hospital specialists initiate these drugs.
These drugs tend to be high cost. This is so users find this information useful for:
- budget setting
- identifying exceptional pressures on individual practices
- reviewing financial performance
A small number of new drugs are added each year, but no previous drugs are removed.
Over time, some of the drugs have become established in routine use, and no longer regarded as specialist.